Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dalpiciclib plus standard endocrine therapy for HR-positive advanced breast cancer
ChiCTR2200061632Phase 4Not yet recruiting
- Sponsor
- Anyang Cancer Hospital
- Start
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of dalpiciclib in breast cancer, sponsored by Anyang Cancer Hospital. Primary endpoints: Progression-Free Survival, Overall Survival and 1 more. Planned start Jun 2022; status: not yet recruiting.
02
Drugs
dalpiciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2200061632.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200061632.